Table 5.
Effectiveness of annual costs during treatment with pioglitazone (monotherapy and combination therapy) in Bulgaria
| Treatment | Number of packs sold in 2014 | Expenses, BGN (EUR) | Number of patients taking DDD | Cost of therapy with PIO or PIO + MET, BGN (EUR) | Difference, BGN (EUR) | Amount reimbursed by the NHIF, BGN (EUR) |
|---|---|---|---|---|---|---|
| SIT | 25,072 | 1,859,840.96 (950,921.58) | 25,072 | 1,177,623.20 (602,109.18) | 682,217.76 (348,812.40) | 682,217.76 (348,812.40) |
| VIL | 6,088 | 233,048.64 (119,155.88) | 3,044 | 142,611.40 (72,916.05) | 90,437.24 (46,239.83) | 90,437.24 (46,239.83) |
| SIT + MET 50/850 mg | 141,986 | 6,325,476.30 (3,234,164.68) | 70,993 | 3,588,696.15 (1,834,871.21) | 2,736,780.15 (1,399,293.47) | 1,368,390.07 (699,646.73) |
| SIT + MET 50/1000 mg | 257,550 | 11,553,693.00 (5,907,309.43) | 128,775 | 6,508,288.50 (3,327,634.81) | 5,045,404.50 (2,579,674.36) | 2,522,702.25 (1,289,837.18) |
| VIL + MET 50/850 mg | 53,980 | 5,255,492.80 (2,687,090.80) | 26,990 | 1,364,344.50 (697,578.27) | 3,891,148.30 (1,989,512.53) | 1,945,574.15 (994,756.27) |
| VIL + MET 50/1000 mg | 128,665 | 11,901,512.50 (6,085,146.72) | 64,332.5 | 3,251,364.55 (1,662,396.30) | 8,650,147.95 (4,422,750.42) | 4,325,074.98 (2,211,375.72) |
| Total: | 613,341 | 37,129,064.20 (18,983,789.08) | 319,206.5 | 16,032,928.30 (8,197,183.96) | 21,096,135.90 (10,786,283.01) | 10,934,395.45 (5,590,649.35) |